Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CALYPTE BIOMEDICAL CORP (CBMC)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
700.2
|
M
| |
|
|
| Market cap: |
$700.2
|
k
| |
|
|
|
Net debt:
|
$64
|
k
| |
|
|
|
EV:
|
$764.2
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($791.0)
|
k
| |
|
|
|
EBIT
|
($956.0)
|
k
| |
|
|
| EPS |
$0.00
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 0.4 | 0.7 | 0.6 | 0.7 | 0.7 | 0.6 | 0.5 | 0.4 |
| Revenue growth | -49.9% | 23.9% | -22.3% | 0.1% | 23.1% | 7.7% | 28.1% | |
| Cost of goods sold | 0.2 | 0.4 | 0.3 | 2.0 | 0.7 | 0.6 | 0.4 | 7.7 |
| Gross profit | 0.1 | 0.3 | 0.3 | -1.3 | 0.0 | 0.0 | 0.2 | -7.3 |
| Gross margin | 38.3% | 40.3% | 53.9% | -172.7% | 5.5% | 5.1% | 27.8% | -1704.9% |
| Selling, general and administrative | 0.7 | 0.8 | 1.0 | 0.0 | 5.9 | 6.4 | 6.0 | 2.2 |
| Research and development | 0.3 | 0.3 | 0.3 | | 1.4 | 1.3 | 1.7 | 2.2 |
| EBIT | -1.0 | -1.0 | 1.2 | -1.3 | -7.2 | -7.6 | -5.9 | -7.3 |
| EBIT margin | -272.9% | -139.2% | 211.3% | -172.7% | -996.8% | -1296.9% | -1073.1% | -1704.9% |
| Pre-tax income | -1.1 | -0.9 | 9.3 | -3.0 | -9.5 | -8.3 | -13.7 | -5.7 |
| Income taxes | 0.0 | -0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 20.4% | 1.9% | 0.1% | 0.0% | | | |
| Net income | -1.1 | -0.7 | 8.8 | -3.6 | -9.5 | -8.3 | -13.8 | -8.8 |
| Net margin | -307.4% | -99.1% | 1567.6% | -497.0% | -1309.0% | -1404.1% | -2513.7% | -2052.2% |
| |
| Diluted EPS | $0.00 | $0.00 | $0.02 | ($0.01) | ($9,526.10) | ($0.03) | ($0.07) | ($0.03) |
| Shares outstanding (diluted) | 666.9 | 545.9 | 487.6 | 450.2 | 0.0 | 275.7 | 202.8 | 175.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|